Focused On-demand Library for Splicing factor YJU2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BW85

UPID:

YJU2_HUMAN

Alternative names:

Coiled-coil domain-containing protein 94

Alternative UPACC:

Q9BW85; O75270; Q9H862; Q9NW16

Background:

Splicing factor YJU2, also known as Coiled-coil domain-containing protein 94, is integral to the spliceosome, facilitating precise mRNA splicing by catalyzing transesterification reactions. This process is crucial for generating mature mRNA from pre-mRNA, involving the removal of non-coding introns and the joining of coding exons. YJU2 enhances the spliceosome's catalytic core stability and aids in the docking process, essential for accurate mRNA synthesis.

Therapeutic significance:

Understanding the role of Splicing factor YJU2 could open doors to potential therapeutic strategies. Its involvement in mRNA splicing and cell protection from TP53-dependent apoptosis upon DNA damage highlights its potential as a target in diseases where these processes are dysregulated.